SCHEMBL21185336

SCHEMBL21185336

COc1ccccc1-c1cc2cc(OCc3ccccc3)ccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.59
MAPT P10636 3/20 0.59
ALDH1A1 P00352 2/20 0.59
HPGD P15428 2/20 0.59
MEN1 O00255 2/20 0.59
RAB9A P51151 2/20 0.59
KMT2A Q03164 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
AURKA O14965 1/20 0.58
KDR P35968 1/20 0.58
SRD5A2 P31213 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
HSD17B10 Q99714 1/20 0.54
FLT3 P36888 1/20 0.54
NPC1 O15118 1/20 0.51
PDGFRB P09619 2/20 0.51
PDGFRA P16234 2/20 0.51
MAOB P27338 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31053089 1.00 KDM4E (0.59) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL21185129 0.85 AURKA (0.60) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL29771199 0.85 AURKA (0.60) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL22628997 0.84 AURKA (0.61) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL29771086 0.84 AURKA (0.61) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL22628568 0.83 FLT3 (0.57) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL31053082 0.83 FLT3 (0.57) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL31053090 0.82 KDM4E (0.68) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL31053108 0.82 AURKA (0.60) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL21185121 0.82 AURKA (0.60) KDM4EMAPTALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497386-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2025-12-16 US disclosed
US-20240308986-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS RADIUS PHARMACEUTICALS, INC. 2024-09-19 US disclosed
US-12018019-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
US-12018019-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
US-20220332704-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS RADIUS PHARMACEUTICALS, INC. 2022-10-20 US disclosed
US-11384068-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2022-07-12 US disclosed
US-11384068-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2022-07-12 US disclosed
US-20200347032-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS RADIUS HEALTH, INC. 2020-11-05 US disclosed
WO-2019144132-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS RADIUS PHARMACEUTICALS, INC. (US) 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347032-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS ESR2, GPER1, ESR1 KDM4E 2441/4885MAPT 3344/4885ALDH1A1 1642/4885
US-20240308986-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS ESR2, GPER1, ESR1 KDM4E 2441/4885MAPT 3344/4885ALDH1A1 1642/4885
US-20220332704-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS ESR2, GPER1, ESR1 KDM4E 2441/4885MAPT 3344/4885ALDH1A1 1642/4885
US-11384068-B2 Estrogen receptor-modulating compounds ESR2, GPER1, ESR1 KDM4E 2441/4885MAPT 3344/4885ALDH1A1 1642/4885
US-12018019-B2 Estrogen receptor-modulating compounds ESR2, GPER1, ESR1 KDM4E 2441/4885MAPT 3344/4885ALDH1A1 1642/4885
US-12497386-B2 Estrogen receptor-modulating compounds ESR2, GPER1, ESR1 KDM4E 2441/4885MAPT 3344/4885ALDH1A1 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.